Long-Term Safety of JAK Inhibitors in Atopic Dermatitis

Panelists discuss how safety remains central in chronic disease management, especially for diverse patient populations, including older adults and those with comorbidities. They review long-term data showing that Janus kinase (JAK) inhibitors such as upadacitinib and abrocitinib maintain favorable safety profiles across years of use, with stable rates of adverse events and no unexpected long-term risks emerging.

Panelists note that older adults achieve comparable efficacy to younger cohorts when appropriately monitored, reinforcing these therapies’ broad applicability. They also address special considerations such as cardiovascular risk, concomitant use with oral contraceptives, and smoking history—explaining that, with proper patient selection and regular assessment, JAK inhibitors remain safe and effective across these scenarios.

The conversation underscores the importance of continued pharmacovigilance and patient education to ensure long-term success. Clinicians are advised to pair evidence-based monitoring with clear communication to maintain both confidence and adherence throughout extended therapy.